Company Overview - Yuneng International (01298.HK) reported a closing price of HKD 1.1 per share, with a significant increase of 15.79% and a trading volume of 3,000 shares, totaling HKD 3,280 [1] - The company has experienced a cumulative increase of 35.71% over the past month, but a year-to-date decline of 4.04%, underperforming the Hang Seng Index by 24.48% [2] Financial Performance - For the fiscal year ending December 31, 2024, Yuneng International achieved total revenue of HKD 534 million, reflecting a year-on-year growth of 68.67% [2] - The net profit attributable to shareholders was HKD 454,700, marking a substantial increase of 109.88% [2] - The company's gross margin stands at 5.18%, with a debt-to-asset ratio of 60.43% [2] Valuation and Industry Comparison - Currently, there are no institutional investment ratings for Yuneng International [3] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -0.03x, with a median of 1.37x [3] - Yuneng International's P/E ratio is exceptionally high at 532.92x, ranking 53rd in the industry, compared to peers such as Jingjiu Kangliao (0.38x), Juxing Medical Holdings (0.4x), and others [3] Business Operations - Yuneng International is a Bermuda-registered investment holding company, listed on the Singapore Exchange in 2004 and on the Hong Kong Stock Exchange in 2011 [3] - The company primarily engages in the distribution and after-sales service of various analytical instruments in China, offering solutions for scientific analysis and testing [3] Upcoming Events - The company is scheduled to disclose its mid-year report for the fiscal year 2025 on August 18, 2025 [4] - A preliminary announcement indicates an expected decline in mid-year earnings for 2025, with a projected loss of approximately HKD 3 million to HKD 2.5 million, representing a year-on-year decrease of 733.33% to 900% [4]
云能国际（01298.HK）8月13日收盘上涨15.79%，成交3280港元